ALVAC-HIV (vCP2438)

AXP000203.1 · Vaccine

Platform
canarypox (ALVAC)
Targets
HIV-1 subtype C gp120; HIV-1 Gag; HIV-1 protease
Originator
Sanofi Pasteur
Sponsor
Sanofi Pasteur

Names

NameTypeSource
ALVAC-HIV (vCP2438)preferred namecurator
ALVAC-HIV vCP2438codepaper
vCP2438codepaper
ALVAC-HIV (subtype C) ambiguoussynonympress

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
canarypox virus (NCBI Taxonomy 44088)
Strain
ALVAC (vCP2438)
Replication
non replicating
Modifications
HIV-1 clade C (ZM96) env gp120 with clade B LAI gp41 anchor, plus LAI gag and protease
Transgenes
HIV-1 env gp120 (clade C ZM96), HIV-1 gag (LAI), HIV-1 protease (LAI)
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03122223Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1/22018-01-162020-07-30160HIV Infections
NCT03284710Safety and Immunogenicity of Clade C ALVAC and gp120 HIV VaccineCompletedPhase 1/22017-06-192019-12-12132HIV Infections
NCT02968849Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South AfricaCompletedPhase 2/32016-10-262021-11-165404HIV Infections
NCT02404311A Safety and Immune Response Study of 2 Experimental HIV VaccinesCompletedPhase 1/22015-02-022018-08-07252HIV Infection

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41121745Large Language Models for Clinical Trial Protocol Assessments.Clinical pharmacology and therapeutics2026cited by trial NCT02968849
PMID 41909709AS01B-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702.Frontiers in immunology2026name in abstract: ALVAC-HIV vCP2438
PMID 40190112A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.Emerging microbes & infections2025cited by trial NCT02404311
PMID 37795976Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.The Journal of infectious diseases2024cited by trial NCT03122223
PMID 38502656Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.PLoS medicine2024cited by trial NCT03284710
PMID 38772835Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.Vaccine2024cited by trial NCT02968849
PMID 39302924Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.PLOS global public health2024cited by trial NCT02404311
PMID 37355583Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline.BMC medical research methodology2023cited by trial NCT02968849
PMID 34895272Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.Trials2021cited by trial NCT02404311
PMID 31999736Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.PloS one2020cited by trial NCT02404311
PMID 32092060Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.PLoS medicine2020cited by trial NCT02404311
PMID 29898870Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.The lancet. HIV2018cited by trial NCT02404311

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40438096Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.Frontiers in immunology2025name in abstract: ALVAC-HIV vCP2438
PMID 30104115In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine.Vaccine2018name in abstract: ALVAC-HIV vCP2438

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC012025Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccinesDIVISION OF BASIC SCIENCES - NCIFRANCHINI, GENOVEFFA2025–2025name in abstract: vCP2438
ZIABC012211Essential Logistic Needs to Implement the C.L.E.A.R. Phase-I HIV Vaccine TrialDIVISION OF BASIC SCIENCES - NCIFRANCHINI, GENOVEFFA2025–2025name in abstract: vCP2438
U19AI142596Core-001DUKE UNIVERSITYHAYNES, BARTON F.2019–2024name in abstract: vCP2438

Notes

Canarypox vector vCP2438, the subtype C adaptation of vCP1521: clade C ZM96 env gp120 with a clade B LAI gp41 anchor, plus LAI gag and protease. Prime in HVTN 100 and the phase 2b/3 HVTN 702 (Uhambo) trial in South Africa (5,407 participants, NIAID), with MF59-adjuvanted bivalent subtype C gp120 protein; vaccinations stopped January 2020 for no efficacy. A different construct from vCP1521, so a separate program.

How to cite

ALVAC-HIV (vCP2438) (AXP000203.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000203.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.